Osteonecrosis - Pipeline Review, H1 2016

Global Markets Direct’s, ‘Osteonecrosis - Pipeline Review, H1 2016’, provides an overview of the Osteonecrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteonecrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteonecrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape of Osteonecrosis
• The report reviews pipeline therapeutics for Osteonecrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Osteonecrosis therapeutics and enlists all their major and minor projects
• The report assesses Osteonecrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Osteonecrosis

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Osteonecrosis
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Osteonecrosis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Osteonecrosis Overview 7
Therapeutics Development 8
Pipeline Products for Osteonecrosis - Overview 8
Osteonecrosis - Therapeutics under Development by Companies 9
Osteonecrosis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Osteonecrosis - Products under Development by Companies 13
Osteonecrosis - Companies Involved in Therapeutics Development 14
Bone Therapeutics SA 14
Enzo Biochem, Inc. 15
K-Stemcell Co., Ltd. 16
Osteonecrosis - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
ALLOB - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CGS-200 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
LWnt-3a - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PREOB - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecule to Agonize LRP for Osteonecrosis Of Jaws - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology and Cardiovascular Disease - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Osteonecrosis - Recent Pipeline Updates 34
Osteonecrosis - Dormant Projects 39
Osteonecrosis - Product Development Milestones 40
Featured News & Press Releases 40
May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB® Phase IIA spinal fusion study 40
Nov 30, 2015: CapGenesis Files Five Orphan Drug Designation Requests with the FDA and EMA for CGS-200 as a Topical Analgesic 40
Dec 04, 2014: Bone Therapeutics Authorised to Enrol Patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB 41
Nov 07, 2013: Bone Therapeutics'' pivotal phase III osteonecrosis trial with PREOB hits a new milestone 42
Jan 28, 2013: Bone Therapeutics Raises €1.6m In Grant Subsidies From SRIW And Sambrinvest For Autologous Bone Cell Therapy 43
Oct 15, 2012: Bone Therapeutics Receives Clearance For Pivotal Phase III Osteonecrosis Trial With Preob In Europe And Treats The First Patients In Study 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 4

List of Tables

Number of Products under Development for Osteonecrosis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Osteonecrosis - Pipeline by Bone Therapeutics SA, H1 2016 14
Osteonecrosis - Pipeline by Enzo Biochem, Inc., H1 2016 15
Osteonecrosis - Pipeline by K-Stemcell Co., Ltd., H1 2016 16
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Stage and Target, H1 2016 19
Number of Products by Stage and Mechanism of Action, H1 2016 21
Number of Products by Stage and Route of Administration, H1 2016 23
Number of Products by Stage and Molecule Type, H1 2016 25
Osteonecrosis Therapeutics - Recent Pipeline Updates, H1 2016 34
Osteonecrosis - Dormant Projects, H1 2016 39

List of Figures

Number of Products under Development for Osteonecrosis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Targets, H1 2016 18
Number of Products by Stage and Targets, H1 2016 18
Number of Products by Mechanism of Actions, H1 2016 20
Number of Products by Stage and Mechanism of Actions, H1 2016 20
Number of Products by Routes of Administration, H1 2016 22
Number of Products by Stage and Routes of Administration, H1 2016 22
Number of Products by Molecule Types, H1 2016 24
Number of Products by Stage and Molecule Types, H1 2016 24